Magic Mushrooms Court Ruling Could Reshape India’s Drug Laws: “It’s A Natural Fungus”
In a landmark decision, the Kerala High Court has ruled that magic mushrooms are neither narcotic nor psychotropic substances under India’s Narcotic Drugs and Psychotropic Substances (NDPS) Act. This judgment arose from the case of Rahul Rai, arrested in October 2024 for possessing charas, ganja, and 226 grams of psilocybin-containing magic mushrooms.
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
Legal Reasoning Behind the Ruling
Justice PV Kunhikrishnan emphasized that mushrooms are natural fungi, not synthetic mixtures, and thus fall outside the NDPS Act’s scope. He noted that the Act does not list mushrooms as scheduled narcotics or psychotropic substances, rendering its quantity-based thresholds inapplicable. This perspective aligns with prior judgments from the Karnataka and Madras High Courts, which also concluded that magic mushrooms cannot be treated as mixtures but are solely fungi.
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
Defense’s Key Arguments
Defense attorney Veena argued that magic mushrooms are not classified as controlled substances under the NDPS Act. She highlighted the absence of specific psilocybin or psilocin content in the chemical analysis report, challenging the assumption that the seized amount constituted a commercial quantity. Veena referenced research indicating that dried Psilocybe cubensis mushrooms contain about 1% psilocybin per gram, suggesting the seized mushrooms likely contained less than the Act’s defined small quantity. She also cited similar cases where courts granted bail due to insufficient evidence of narcotic content.
Implications for India’s Drug Laws
This ruling could prompt a reevaluation of India’s drug policies, especially concerning substances with potential medical applications. Research indicates that psilocybin may be effective in treating conditions like treatment-resistant depression, cancer-related depression, obsessive-compulsive disorder, and cluster headaches. Advocates suggest that such substances should be regulated for therapeutic use under the Drugs and Cosmetics Act. However, medical professionals caution that psilocybin, a hallucinogen, can induce psychotic symptoms and may trigger mental health issues in susceptible individuals. They emphasize the need for thorough clinical research before considering legalization or decriminalization.
The Kerala High Court’s decision marks a pivotal moment in India’s legal approach to psychedelic substances. By distinguishing natural fungi from narcotics, the court has set a precedent that may influence future cases and legislative reforms. As global attitudes toward psychedelics evolve, India faces the challenge of balancing potential therapeutic benefits with public health considerations.
